Company
Meto
Meto publishes compounded semaglutide at $199 a month — GLP-1 family protocol.
- 1 program
- 1 molecule
- 1 reading
Read from meto.co on September 2, 2026. This page records what the company publishes. It is not a review and takes no position on the company.
Go to Meto
We earn nothing from this link. Meto has no commercial arrangement with Treatment Registry, and its record here is kept to the same standard as every other.
What it costs
first month, including the required fees on record · ◯ $199 advertised · GLP-1 family protocol
Terms
| Membership | Required, $29 per month. Membership $29/month, billed at $320 annually. "Your membership unlocks clinician access and platform tools; peptide protocols are billed monthly based on the medication you're on", and the plan states "Cost of medication not included." ⛔ $29 × 12 is $348, so the annual price is a discount on the monthly rate rather than a restatement of it. |
|---|
Not yet checked: pharmacy, consultation fee and states.
Terms can differ between this company’s programs; each entry carries its own.
Programs
Notes
Recorded against this company rather than one program.
September 2, 2026
- 1. Meto is a labs-first peptide platform; its 'GLP-1 family' protocol ($199/mo) is a single SKU covering EITHER compounded semaglutide (2.5 mg/mL) or tirzepatide (10 mg/mL) at the same price point, chosen by the clinician based on labs — not two separately priced products. On top of the $199/mo protocol price, every member also pays a separate $29/month membership fee that explicitly excludes medication cost, plus a one-time $149 lab panel required before matching to a protocol (not a recurring price, so not recorded as an entry).
Before you act
Cite this
Treatment Registry. (2026). Meto: recorded programs and prices. Last verified September 2, 2026. Retrieved [your access date], from https://treatmentregistry.com/providers/meto